Pre-made Befovacimab benchmark antibody ( Whole mAb, anti-TFPI therapeutic antibody, Anti-EPI/LACI/TFI Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Befovacimab biosimilar, Whole mAb, Anti-TFPI Antibody: Anti-EPI/LACI/TFI therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Befovacimab (formerly BAY 1093884) is an anti-tissue factor pathway inhibitor (anti-TFPI) antibody being developed by Bayer for the treatment of haemophilia.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-053-1mg	1mg	3090
GMP-Bios-ab-053-10mg	10mg	Inquiry
GMP-Bios-ab-053-100mg	100mg	Inquiry
GMP-Bios-ab-053-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Befovacimab biosimilar, Whole mAb, Anti-TFPI Antibody: Anti-EPI/LACI/TFI therapeutic antibody
INN Name	Befovacimab
Target	TFPI
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	na
Conditions Approved	na
Conditions Active	Haemophilia
Conditions Discontinued	na
Development Tech	na